Key Takeaways:
The Food and Drug Administration granted accelerated approval to Vera Therapeutics Inc.'s Trutakna for adults with primary IgA nephropathy, making it the first and only available therapy that targets both BAFF and APRIL — the two cytokines driving the autoimmune kidney disease. Patients treated with Trutakna achieved a 46% reduction from baseline in proteinuria, with a 42% reduction compared with placebo (p<0.0001) at 36 weeks in the Phase 3 ORIGIN 3 trial.
"The approval of Trutakna as the first and only BAFF and APRIL inhibitor for IgAN marks an important milestone and we believe it has the potential to meaningfully transform the treatment landscape," Marshall Fordyce, founder and chief executive officer of Vera Therapeutics, said.
Trutakna (atacicept-vymj) is a soluble recombinant fusion protein containing the TACI receptor that binds to BAFF and APRIL, blocking the B-cell activation that produces the autoantigen Gd-IgA1 and its autoantibodies. These immune complexes deposit in the kidneys, causing inflammation and progressive damage. Participants treated with Trutakna also experienced a 68% reduction in galactose-deficient IgA1, a secondary endpoint. The drug is self-administered at home via a once-weekly 150 mg subcutaneous autoinjector.
IgA nephropathy affects approximately 160,000 patients in the U.S. and roughly 2.5 adults per 100,000 globally each year, most often diagnosed between ages 30 and 40. At least 50% of patients may progress to kidney failure or death within 10 to 20 years of diagnosis, according to published research. The accelerated approval is based on proteinuria reduction as a surrogate endpoint; continued approval depends on verification of clinical benefit in the ongoing ORIGIN 3 trial, which continues in a blinded manner to evaluate change in kidney function measured by estimated glomerular filtration rate, with results anticipated in the third quarter of 2026.
Mechanism and Safety Profile
Trutakna's dual inhibition of BAFF and APRIL distinguishes it from existing IgAN therapies, which typically target downstream inflammation rather than the upstream B-cell drivers. The ORIGIN 3 trial enrolled 428 patients, with Trutakna generally well tolerated. The most common adverse reactions were infections (32% vs 28% for placebo) and local administration reactions (30% vs 5%). No serious, severe or opportunistic infections or hypogammaglobulinemia were observed in Trutakna-treated patients, and most adverse reactions were mild or moderate in severity, resolving without treatment interruption.
Market and Competitive Landscape
Vera shares rose 6.2% in afternoon trading following the approval, according to Reuters data. The Brisbane, California-based company, founded in 2016, now faces the commercial challenge of launching a first-in-class therapy against established treatments including SGLT2 inhibitors and corticosteroids. The company launched TRUTAKNA TRU SUPPORT, a patient support program offering insurance coverage assistance and copay options that could bring eligible commercially insured patients' out-of-pocket costs to as little as zero dollars.
The confirmatory eGFR data due in Q3 2026 will be critical for full approval and for differentiating Trutakna against potential competitors in the IgAN space, including Calliditas Therapeutics' Tarpeyo and Novartis' iptacopan. Vera had not yet disclosed its cash runway as of the approval announcement, though the company's transition to a commercial-stage biotech will increase its operating expenses as it builds out sales and patient support infrastructure.
This article is for informational purposes only and does not constitute investment advice.
